• All Solutions All Solutions Caret
    • Editage

      One platform for all researcher needs

    • Paperpal

      AI-powered academic writing assistant

    • R Discovery

      Your #1 AI companion for literature search

    • Mind the Graph

      AI tool for graphics, illustrations, and artwork

    • Journal finder

      AI-powered journal recommender

    Unlock unlimited use of all AI tools with the Editage Plus membership.

    Explore Editage Plus
  • Support All Solutions Support
    discovery@researcher.life
Discovery Logo
Paper
Search Paper
Cancel
Ask R Discovery Chat PDF
Explore

Feature

  • menu top paper My Feed
  • library Library
  • translate papers linkAsk R Discovery
  • chat pdf header iconChat PDF
  • audio papers link Audio Papers
  • translate papers link Paper Translation
  • chrome extension Chrome Extension

Content Type

  • preprints Preprints
  • conference papers Conference Papers
  • journal articles Journal Articles

More

  • resources areas Research Areas
  • topics Topics
  • resources Resources

Low Total Testosterone Research Articles

  • Share Topic
  • Share on Facebook
  • Share on Twitter
  • Share on Mail
  • Share on SimilarCopy to clipboard
Follow Topic R Discovery
By following a topic, you will receive articles in your feed and get email alerts on round-ups.
Overview
494 Articles

Published in last 50 years

Related Topics

  • Low Free Testosterone
  • Low Free Testosterone
  • Low Testosterone Levels
  • Low Testosterone Levels
  • Low Serum Testosterone
  • Low Serum Testosterone
  • Serum Total Testosterone
  • Serum Total Testosterone
  • Low Testosterone
  • Low Testosterone

Articles published on Low Total Testosterone

Authors
Select Authors
Journals
Select Journals
Duration
Select Duration
468 Search results
Sort by
Recency
Reevaluating the Threshold for Low Total Testosterone.

Reevaluating the Threshold for Low Total Testosterone.

Read full abstract
  • Journal IconClinical chemistry
  • Publication Date IconApr 16, 2025
  • Author Icon Adith S Arun + 3
Cite IconCite
Chat PDF IconChat PDF
Save

Association between low basal serum total testosterone levels and the risk of recurrent pregnancy loss in women with infertility.

Association between low basal serum total testosterone levels and the risk of recurrent pregnancy loss in women with infertility.

Read full abstract
  • Journal IconEuropean journal of obstetrics, gynecology, and reproductive biology
  • Publication Date IconApr 1, 2025
  • Author Icon Yang Zhao + 6
Cite IconCite
Chat PDF IconChat PDF
Save

Determination of Testosterone level as predictor for insulin resistance in young men with family history of type2 diabetes and hypertension.

Background: Insulin resistance is associated with metabolic syndrome , type 2 diabetes and representing a risk factor for cardiovascular disease . This relationship may be modulated to some extent by age related changes in sex hormone status.. In particular, reduced total testosterone (TT) levels have been associated with insulin resistance and subsequent risk for developing type 2 diabetes. Aim of study: we examined whether low total testosterone level were associated with insulin resistance in young adult men. Methods: a total of 83 men (young adult men) divided into 2 group : (group1 ) 49 men with a risk factor for insulin resistance(with a family history of type2 diabetes and hypertension) and (group2) 34 men without any risk factor aged (20-40) years. Age, body mass index (BMI) and waist circumference were measured. Early morning, they were assayed for total testosterone, and insulin levels. Insulin resistance was assessed using a homeostatic model (HOMA-IR). Results: Total testosterone, declined progressively across increasing quintiles of HOMA-IR as a mean of(4.49±1.87) ng/ml in group1 compared mean (7.82±2.21) ng/ml in group 2 and correlated inversely with HOMA-IR( r = -0.424 , p = 002) also with insulin (r= -0.541) (p< 0.0001) in group1 . Total testosterone correlated inversely with BMI (r=-0.471 , p=0.001) in group1. There is a significant positive correlation between HOMA- IR of group1 and BMI (r= 0.472) (p

Read full abstract
  • Journal IconBaghdad Science Journal
  • Publication Date IconJan 14, 2025
  • Author Icon Bushra F Hasan + 2
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Association between cardiometabolic index and risk of testosterone deficiency in adult men: a cross-sectional study

BackgroundMetabolic health is closely related to testosterone levels, and the cardiometabolic index (CMI) is a novel metabolic evaluation metric that encompasses obesity and lipid metabolism. However, there is currently a lack of research on the relationship between CMI and testosterone, which is the objective of this study.MethodsThis study utilized data from the National Health and Nutrition Examination Survey (NHANES) cycles from 2011 to 2016. Only adult males who completed physical measurements, lipid metabolism assessments, and testosterone measurements were included in the final analysis. The exposure variable CMI was analyzed both as a continuous variable and a categorical variable divided into quartiles. Testosterone was measured using the isotope dilution liquid chromatography-tandem mass spectrometry technique. Linear and logistic regression analyses were used to explore the relationship between CMI and total testosterone (TT) levels, as well as the risk of testosterone deficiency (TD). Smooth curve fittings were employed to visualize their linear relationships. Subgroup analyses were conducted to evaluate the stability of our results across different participant characteristics. Finally, ROC analysis was used to assess the performance of CMI in predicting TD.ResultsA total of 2,747 participants were included in the analysis, including 552 with TD (20.10%). The average CMI of the sample was 1.59 ± 0.03, with TD participants having a higher CMI of 2.18 ± 0.08 compared to non-TD participants at 1.46 ± 0.03. Corresponding testosterone levels were 223.79 ± 3.69 ng/dL and 508.36 ± 5.73 ng/dL, respectively. After adjusting for all covariates, participants with higher CMI showed lower TT (β = -23.84, 95% CI: -33.94, -13.74, p < 0.0001) and a higher risk of TD (OR = 1.26, 95% CI: 1.08, 1.48, p = 0.01). When CMI was categorized into quartiles with Q1 as the reference, participants in Q4 exhibited significantly lower TT (β = -74.04, 95% CI: -106.01, -42.08, p < 0.0001) and a higher risk of TD (OR = 2.34, 95% CI: 1.18, 4.64, p = 0.02). Smooth curve fittings indicated a linear relationship between these variables. Subgroup analyses confirmed the stability of these associations across different population characteristics. ROC curve analysis demonstrated that CMI had good predictive performance for TD with a cut-off value of 1.126 and an AUC (95% CI) of 0.673 (0.649, 0.700).ConclusionCMI is associated with lower TT and a higher risk of TD, and it can predict the risk of TD. Using CMI for early detection and timely intervention could reduce the disease burden and promote reproductive health. Further prospective studies with large sample sizes are needed to validate these findings.

Read full abstract
  • Journal IconBMC Public Health
  • Publication Date IconJan 6, 2025
  • Author Icon Yangyang Mei + 6
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Association between serum testosterone level and cardiovascular health in US male adults: results from the 2013-2016 NHANES.

There have been many studies of the association between testosterone and cardiovascular disease (CVD). However, limited research has examined the association between testosterone and Life's Essential 8 (LE8), a recently updated algorithm for assessing cardiovascular health (CVH). This study aims to investigate the association between serum total testosterone (TT) levels and LE8 scores-where higher LE8 scores indicate better CVH-among adult males in the United States. Data from 3308 adult males were extracted from the National Health and Nutrition Examination Survey conducted between 2013 and 2016. Weighted univariate and multivariate linear regression models [β and 95% confidence intervals (CIs)] and logistic regression models [odds ratios (ORs) and 95% CIs] were used to explore the association between testosterone and LE8 and high CVH risk. Additionally, a smoothed curve fit (penalized spline method) and generalized additive model regression were applied to further explore these relationships. LE8 includes 4 health behaviors (nicotine exposure, diet, physical activity, and sleep duration) and 4 health factors (body mass index, non-high-density lipoprotein cholesterol, blood pressure, and blood glucose). Serum TT levels were strongly associated with LE8 scores after adjusting for all confounders (continuous: β = 2.75, 95% CI: 1.92, 3.57, P < .0001; quartiles: Q4 vs Q1: β = 3.89, 95% CI: 2.78, 5.01, P < .0001). Similarly, high levels of TT were associated with a significantly lower CVH risk (OR = 0.59, 95% CI: 0.49, 0.73, P < .001). Compared to low TT levels, normal TT levels significantly reduced the risk of CVH (OR = 0.51, 95% CI: 0.38, 0.69, P < .001). Smoothed curve fitting showed a positive linear correlation between TT levels and LE8 scores, as well as a consistent linear negative correlation with CVH risk. These findings highlight the importance of endogenous TT levels in promoting CVH and provide new insights into factors influencing CVH. This study is the first to investigate the association between serum TT level and LE8 scores as well as LE8-assessed CVH among adult males. However, the observational nature of this study precludes any assessment of causality. This study demonstrates a robust positive association between serum TT levels and LE8 scores in a nationally representative sample of adult men in the United States.

Read full abstract
  • Journal IconThe journal of sexual medicine
  • Publication Date IconJan 4, 2025
  • Author Icon Xu Wu + 2
Cite IconCite
Chat PDF IconChat PDF
Save

Improved gonadal hormones levels following 6 and 12 months of anti-retroviral therapy among men living with human immunodeficiency virus infection.

Male hypogonadism is commonly reported in men living with human immunodeficiency virus (HIV) (MLWH), reaching a prevalence of up to 89% and shown to decrease in the antiretroviral therapy (ART) era as compared to pre-ART era. Data regarding the effect of ART on gonadal hormones levels are scarce. We aimed to determine changes in gonadal hormones levels in HIV males following ART initiation. This was a longitudinal study involving newly diagnosed ART naïve MLWH in Mwanza, Tanzania. All enrolled participants underwent thorough clinical and physical examination including anthropometric measurements. A pre-structured questionnaire was used to collect socio-demographic and clinical data. Serum total testosterone (TT), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol were estimated at baseline, six and twelve months after ART initiation. Serum TT < 300 ng/dl, or ≥300 ng/dl with high LH and FSH were taken as markers of hypogonadism. Data were analyzed using STATA version 15. A total of 213 participants were enrolled in this study. Between individual's pairs, the median levels of TT and LH after six and twelve months were found to be significantly higher while estradiol was significantly lower than at baseline (p < 0.001). Between after six and after twelve months, only median estradiol levels showed significant change with levels being lower after twelve months (p < 0.001). The change in FSH was not statistically significant. Of the 89 participants (41.8%) who had hypogonadism at baseline, 44 (49.4%) normalized TT (≥300 ng/ml) and had higher median testosterone than those who did not normalize. Furthermore, there was a statistically significant association between testosterone change and initial viral load (p = 0.049), WHO clinical stage (p = 0.031) and baseline hypogonadism status (p = 0.014). This study concludes that TT improved significantly after ART initiation. Particularly, half of the MLWH who presented with low TT at baseline normalized it within the first year of treatment. Therefore, ART reduces prevalence of hypogonadism and baseline TT seems to be predictive of future evolution of the hypogonadism.

Read full abstract
  • Journal IconPloS one
  • Publication Date IconJan 1, 2025
  • Author Icon Shabani Iddi + 4
Cite IconCite
Chat PDF IconChat PDF
Save

Basal serum luteinizing hormone, total testosterone, and free testosterone levels do not impact IVF outcomes in patients with polycystic ovary syndrome.

To assess the influence of basal serum levels of luteinizing hormone (LH), total testosterone (TT), and free testosterone (FT) on in vitro fertilization (IVF) success rates in patients with polycystic ovary syndrome (PCOS). A retrospective cohort analysis of PCOS patients who underwent freeze-all, gonadotropin releasing hormone (GnRH) antagonist IVF protocols from January 2013 to December 2019. Patients were grouped based on median basal serum levels of LH, TT, and FT to compare their IVF outcomes. A total of 76 women with PCOS diagnosed as per the 2003 Rotterdam criteria were included. When analyzed by LH levels, groups had similar baseline characteristics except for higher mean ± standard deviation TT (1.4±0.9 vs. 1.9±0.9 nmol/L, p=0.02) and FT (0.6±0.5 vs. 0.9±0.5 nmol/L, p=0.03) in the elevated LH group. However, clinical pregnancy rates (CPR) (34.2% vs. 44.7%, p=0.35) and live birth rates (LBR) (21.0% vs. 31.6%, p=0.29) were not different. The group with lower TT had more previous pregnancies (0.9±1.2 vs. 0.3±0.7, p=0.02) and shorter infertility duration (2.3±2.0 vs. 3.7±2.7 years, p=0.04), but again CPR (46.8% vs. 42.8%, p=0.90) and LBR (37.5% vs. 25.7%, p=0.33) were similar. FT analysis revealed no significant differences in CPR (48.2% vs. 36.7%, p=0.36) and LBR (23.2% vs. 37.9%, p=0.22) despite higher TT (1.1±0.4 vs. 2.2±1.1 nmol/L, p<0.001) and LH (6.1±3.8 vs. 11.2±7.2 IU/L, p<0.001) in the high FT group. Basal serum levels of LH, TT, and FT did not significantly affect IVF outcomes in patients with PCOS using GnRH antagonist, freeze-all protocols.

Read full abstract
  • Journal IconJournal of the Turkish German Gynecological Association
  • Publication Date IconDec 10, 2024
  • Author Icon Nir Kugelman + 6
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Association of Di(2-ethylhexyl) Phthalate Exposure with Reproductive Hormones in the General Population and the Susceptible Population: A Systematic Review and Meta-Analysis.

Di(2-ethylhexyl) phthalate (DEHP), an environmental endocrine disruptor, has hormone-like activity and endocrine-disrupting effects. However, the types of reproductive hormones associated with DEHP vary across the studies. Thus, we conducted a systematic review and meta-analysis to pool existing epidemiological evidence. We searched three databases up to January 31, 2024, for eligible original studies to ultimately include 37 studies from eight countries with a total of 28 911 participants. DEHP exposure was evaluated with urinary metabolites. Since the main types, production sites, blood concentrations, and functions of reproductive hormones differ between men and women, we reported the combined effect values by gender. Subgroup analyses were conducted by age, subfertility status, and the national sociodemographic index (SDI) level. Furthermore, the effect of maternal exposure during pregnancy on children's reproductive hormone levels was analyzed separately. Overall, in general, in men, DEHP was positively correlated with sex hormone binding-globulin (SHBG) and adversely correlated with total testosterone (TT), free androgen index (FAI), and follicle-stimulating hormone (FSH). Results indicated that among men of reproductive age, DEHP exposure was associated with more significant hormonal suppression in infertile men compared with fertile men. Notably, age subgroup analysis among women revealed that postmenopausal women were more vulnerable to DEHP, which was related to lower TT and estradiol (E2). However, this study did not observe a significant association between prenatal DEHP metabolites and reproductive hormone levels in children. Our research identifies the most susceptible hormones (androgen suppression) after DEHP exposure and suggests that infertile men and postmenopausal women are in great need of more attention as sensitive populations.

Read full abstract
  • Journal IconEnvironment & health (Washington, D.C.)
  • Publication Date IconNov 15, 2024
  • Author Icon Xuanxuan Li + 34
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Association of serum testosterone levels with left atrial size, function, and risk of atrial fibrillation in adult men: observational and mendelian randomization analyses

Abstract Background Numerous studies have investigated the association between serum testosterone levels, testosterone replacement therapy (TRT), and cardiovascular risk. However, research examining the relationship between testosterone levels and atrial fibrillation (AF) risk remains limited. We comprehensively analyzed the association between total testosterone (TT) levels, intermediary phenotypes such as left atrium (LA) size and function, and the risk of AF in middle-aged and older men. Methods We utilized data from the UK Biobank, a population-based prospective cohort, focusing on 179,988 White men who had complete serum TT level data and no AF history. Observational associations between TT levels and LA imaging traits, as well as AF risk, were estimated using multivariable regression and time-dependent Cox regression models, treating TT levels as a time-varying variable. Genetic associations were examined by Mendelian randomization (MR), using both UK Biobank and external large consortia genome-wide association study data. Results During the median follow-up of 11.8 years (IQR 10.9–12.5), we observed 13,847 incident AF cases (7.7%). Participants with normal TT levels (≥ 300 ng/dL) showed a 15% reduced risk of AF (HR of 0.85 [95% CI, 0.82–0.89]) compared to those with low TT (&amp;lt; 300 ng/dL). Interestingly, participants undergoing TRT experienced a 51% higher risk of AF (1.51 [1.09–2.07]). Furthermore, each 1-standard deviation increase in TT levels was associated with a reduced AF risk (OR of 0.91 [0.89–0.93]) and an improved LA emptying fraction (1.29 [1.06–1.58]). Applying age-specific cutoff values for low TT levels highlighted a more pronounced AF risk reduction in participants with normal TT. MR analyses supported these observations, suggesting potential causal relationships between TT levels and both LA function and AF risk. Conclusions Our findings suggest that low TT levels are associated with reduced LA function and increased risk of AF, both observationally and genetically, indicating that serum TT could serve as a surrogate marker or even a potential causal mediator in the development of AF.Abstract tableAbstract figure

Read full abstract
  • Journal IconEuropean Heart Journal
  • Publication Date IconOct 28, 2024
  • Author Icon S H Cho + 9
Cite IconCite
Chat PDF IconChat PDF
Save

High SHBG and Low Bioavailable Testosterone are Strongly Causally Associated with Increased Forearm Fracture Risk in Women: An MR Study Leveraging Novel Female-Specific Data

The effects of androgens on women’s bone health are not fully understood. Mendelian randomization (MR) studies using sex-combined data suggest that sex hormone-binding globulin (SHBG) and bioavailable testosterone (BioT) causally affect bone traits. Given significant sex differences in hormone regulation and effects, female-specific MR studies are necessary. In the current study, we explored the causal relationships of SHBG, BioT, and total testosterone (TT) with forearm fracture (FAFx) risk in women using two-sample MR analyses. We utilized a unique female-specific FAFx outcome dataset from three European biobanks (UFO, HUNT, Estonian Biobank) comprising 111,351 women and 8823 FAFx cases, along with female-specific genetic instruments of SHBG, BioT, and TT identified in the UK Biobank. We also assessed bone mineral density (BMD) at the forearm (FA), femoral neck (FN), and lumbar spine (LS) using female-specific GWAS data from the GEFOS consortium. High SHBG (odds ratio per standard deviation increase (OR/SD): 1.53, 95% confidence intervals (CIs): 1.34–1.75), low BioT (OR/SD: 0.77, 0.71–0.84) and low TT (OR/SD 0.90, 0.83–0.98) were causally associated with increased FAFx risk. BioT was positively, and SHBG inversely, causally associated with especially FA-BMD, but also LS-BMD and FN-BMD, while TT was only significantly positively associated with FA-BMD and LS-BMD. We propose that endogenous androgens and SHBG are important for women’s bone health at distal trabecular-rich bone sites such as the distal forearm and may serve as predictors for FAFx risk.

Read full abstract
  • Journal IconCalcified Tissue International
  • Publication Date IconOct 16, 2024
  • Author Icon Johan Quester + 14
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

7238 A rare cause of primary ovarian failure in an adolescent due to a genetic mutation in mitochondrial poly-A-polymerase (mTPAP) mRNA

Abstract Disclosure: J. Epstein: None. S. Veera: None. J. Pappas: None. B.C. Shah: None. Primary ovarian insufficiency (POI) is a dysfunction or loss of ovarian follicles with associated amenorrhea. While most causes are idiopathic, approximately 15% of POI cases are due to single gene or chromosomal abnormalities, such as X chromosome abnormalities. Many of these nuclear genes encode for proteins that function within the mitochondria. Mitochondrial disorders affect tissues with high energy demand, such as the neurological, skeletal, cardiac, and endocrine systems. Furthermore, mature ovaries have a relatively higher concentration of mitochondria, which play a role in cellular respiration along with steroidogenesis. Mutations that disrupt these pathways can therefore lead to ovarian dysfunction. We present a case of a 17-year-old female with concern for primary amenorrhea. She underwent pubarche at age 12 years and thelarche at 14 years, with slowed progression. Height Z score was -1.61 and weight Z score was -0.41. Lab work at presentation was significant for LH 18.6 IU/L (N 2.4-12.6 IU/L), FSH 43.9 IU/L (N 1.1-9.6 IU/L), low estradiol &amp;lt;2.5 pg/mL (N 30-100 pg/mL), low total testosterone 8.3 ng/dL (N 15-31 ng/dL), unremarkable HbA1C, cortisol, thyroid levels, and a 46 XX karyotype. Pelvic ultrasound showed small ovarian volumes with a 1.9 cc right ovary, 1.5 cc left ovary consistent with lack of hormonal stimulation, and uterus length of 4.9 cm (N &amp;gt; 4 cm) consistent with early hormonal stimulation. She was started on transdermal estrogen replacement. Past medical history included stable pericardial effusion, episodes of supraventricular tachycardia, pre-cataracts, speech delays, mild learning disabilities, spastic diplegia, progressive gait abnormalities, ligamentous laxity, and recurrent patellar dislocations requiring multiple orthopedic limb surgeries. Family history was significant for parental consanguinity as first cousins. As the etiology of the POI remained unknown, genetic testing was completed. Whole exome sequencing (WES) revealed a homozygous pathogenic variant in the MTPAP gene: p.(Leu495Arg) (CTG&amp;gt;CGG): c.1484 T&amp;gt;G in exon 9 on chromosome 10p11.23. MTPAP, also known as SPAX4, TENT6, or PAPD1, is a nuclear-encoded polymerase involved in synthesizing the 3’ poly(A) tail of mitochondrial transcripts as well as in mRNA degradation. She was diagnosed with autosomal recessive MTPAP-related neurodevelopmental and movement disorder. Monogenic disorders affecting mitochondrial function are rare causes of POI. A high index of suspicion should be raised when a constellation of neurological, musculoskeletal, and cardiac problems co-exist. WES can be a very useful tool for uncovering rare genetic disorders. Further studies are needed to clarify details of organ specific mitochondrial dysfunction and possible therapeutics in individuals affected with MTPAP-related neurodevelopmental and movement disorders. Presentation: 6/1/2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Jessy Epstein + 3
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

SUN-415 Medical Therapy to Restore Male Fertility in Classic Congenital Adrenal Hyperplasia

Abstract A.J. Newman: None. L.C. Tsai: None. A. Vaidya: None. Classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) causes excess adrenal androgens that may suppress the hypothalamic-pituitary-gonadal axis leading to male infertility. A 35-year-old man with classic CAH presented with his wife after 2 years of inability to conceive and an extensive evaluation for female factors of infertility that was unrevealing. He had been diagnosed with CAH in infancy after a salt-wasting crisis. At the time of this evaluation, his medication regimen included hydrocortisone 20 mg in the morning and 5 mg in the afternoon, plus fludrocortisone 0.2 mg daily. He felt well on this regimen, with good strength, energy and sexual function. He was normally virilized and ultrasound showed testes of normal size without evidence of testicular adrenal rest tumors (TARTs). Semen analysis demonstrated sperm count of 14.7 million/mL (normal &amp;gt; 15 million/mL) with 98% abnormal morphology. Labs were notable for elevated 17-hydroxyprogesterone (17-OHP) 18,400 ng/dL (&amp;lt;220) and androstenedione (A4) 1,390 ng/dL (40-150); low total testosterone (T) 199 ng/dL (240-950) and free T 3.38 ng/dL (4.65-18.1); and low luteinizing hormone (LH) 0.2 IU/L (1.7-8.6) and follicle stimulating hormone (FSH) 1.1 IU/L (1.5-12.4). Androstenedione to total testosterone ratio (A:T) was 7.7 (reference &amp;lt; 1). His infertility was attributed to high adrenal androgens resulting in suppression of gonadotropins. He was treated with a nighttime dose of methylprednisolone 3 mg in addition to his current regimen. Five months later, his labs showed 17-OHP 3100 ng/dL, A4 160 ng/dL, total T 550 ng/dL (A:T ratio 0.29), free T 9.90, FSH 6.9 IU/L and LH 4.3 IU/L; repeat semen analysis demonstrated sperm count of 125 million/mL with normal morphology and motility. The patient’s wife achieved a spontaneous pregnancy 3 months later with subsequent delivery of a healthy baby girl. Of note, while addition of nighttime methylprednisolone restored the patient’s fertility, it also led to 15 lb. weight gain in 6 months, and therefore nocturnal methylprednisolone was discontinued. In all patients with classic CAH, treatment entails glucocorticoid and mineralocorticoid replacement to treat adrenal insufficiency and to partially lower ACTH, adrenal hyperandrogenism, and the risk of TARTs. This therapy must be balanced with the risk of iatrogenic Cushing syndrome, as ACTH suppression invariably requires supraphysiologic glucocorticoids. Though adrenal hyperandrogenism contributes to infertility, in male patients not seeking fertility, adrenal androgens may adequately support virilization and sexual function, so suppression may not be needed to achieve patient goals. However, in those seeking fertility, temporary use of nocturnal glucocorticoids can effectively reverse hyperandrogenemia and restore spermatogenesis and fertility. Sunday, June 2, 2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Andrew J Newman + 2
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

SUN-519 Kallman Syndrome in an Australian First Nations patient with Bigender Gender Identity

Abstract M. Balcerek: None. B. Nolan: None. J. MacLeod: None. Background: Australia’s First Nations (Aboriginal and Torres Strait Islander) peoples represent ∼4% of the Australian population. First Nations peoples have diverse concepts of gender identity that extend beyond typical Western binary and nonbinary constructs. They also have higher rates of mental illness and socioeconomic disadvantage compared to non-indigenous Australians, with similar health disparities experienced by transgender, gender diverse and nonbinary Australians. Clinical case: A 57-year-old Australian Aboriginal patient (recorded male at birth) was referred to the Gender Service for evaluation of gender incongruence by their primary care provider. The patient described negative health care experiences due to misgendering. They disclosed a bigender gender identity (both male and female), an identity embraced and celebrated in their culture. There was no dysphoria relating to their sex recorded at birth, nor physical characteristics. Their main concern was osteoporosis management, and they were subsequently referred to Endocrinology. The presence of hypogonadotrophic hypogonadism and anosmia previously prompted karyotyping, confirming a diagnosis of Kallman Syndrome. Their medical history included type 2 diabetes mellitus (T2DM) with suboptimal glycaemic control, microvascular/macrovascular complications, and autonomic dysfunction. Cardiovascular risk factors included hypertension, dyslipidaemia, and class III obesity. Osteoporosis was diagnosed in the setting of multiple previous fragility fractures. Medications included Sitagliptin/Metformin (50/1000mg bd), Insulin Aspart/Insulin Aspart Protamine (30/70 units/mL) 80 units bd, Perindopril/Amlodipine (10/10mg daily), Simvastatin 40mg daily and Pregabalin 100mg daily. They were previously treated with testosterone for pubertal induction; however, this was self-ceased at age 40 years due to perceived lack of benefit. They were not on hormonal therapy, with low serum total testosterone and estradiol concentrations (1.1 nmol/L and 72 pmol/L via immunoassay respectively), and inappropriately low gonadotrophins (FSH 0.1, LH &amp;lt;0.1 IU/L). Transdermal estradiol 0.1% (2mg daily) was commenced to target an estradiol concentration &amp;gt;200 pmol/L for bone health, rather than for feminisation. Their diabetes therapy was intensified, and they were counselled on cardiovascular risk modification. Discussion: Our case is the first report of an Australian First Nations person with Kallman syndrome and bigender gender identity, treated with both masculinising and feminising hormone therapy across their lifetime. Important medical considerations include the physiologic effect of masculinising and feminising hormones on their T2DM, cardiometabolic risk factors and osteoporosis. Culturally responsive gender affirming health care and trauma-informed practice were also essential. Sunday, June 2, 2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Matthew Balcerek + 2
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

8059 An Interesting Case Of Hypogonadism Likely Caused By Cushing's Syndrome

Abstract Disclosure: R. Ripa: None. J. Su: None. R. Patel: None. Introduction: Cushing’s Syndrome is a rare endocrine disorder that comprises a multitude of symptoms caused by hypercortisolism. Given non-specific symptoms, the disease can often be overlooked for more common diseases, such as diabetes, obesity, and even hypogonadism. Hypogonadism is a clinical disorder defined by decreased functional activity of the gonads. The diagnosis can often be challenging in developed males, who present with hypogonadotropic hypogonadism without an obvious cause. Here we present a case of a male who presented with hypogonadism symptoms for at least 5 years before being diagnosed with Cushing’s syndrome. Case Presentation: 58-year-old Caucasian male with a medical history of hypertension, cardiomyopathy and a BMI of 23, presented with decreased libido and erectile dysfunction. He was started on testosterone therapy three years prior, however it was discontinued due to heart failure. Without testosterone replacement, lab work was notable for: low free and total testosterone, 21.4 and 50.6 ng/dL, respectively, inappropriately normal findings of LH, FSH (1.0 and 4.9 IU/L, respectively), as well as unremarkable findings of GH, Prolactin, TSH, pituitary MRI and testes ultrasound, leading to a suspicion of hypogonadism. Due to persistent symptoms of hypogonadism and low testosterone, clomiphene was started but later changed to testosterone therapy after cardiology consultation. Shortly after, he began reporting facial flushing, associated with facial roundedness and elevated blood pressure. Upon further work up, hyperaldosteronism and pheochromocytoma testing was negative and his baseline cortisol was 21.9 mcg/dL with a low adrenocorticotropic hormone (ACTH), &amp;lt;5 pg/mL. Further, dexamethasone suppression testing showed suboptimally suppressed cortisol (14.4 mcg/dL). An abdomen MRI with and without contrast revealed a 2.3 cm adrenal adenoma, confirming an adrenal source of Cushing’s syndrome, and he underwent an adrenalectomy. Post-procedure, his cortisol and ACTH levels normalized to 10.5 mcg/dL and 39 pg/mL, respectively, showing a revival of his hypothalamic - pituitary - adrenal axis. Unfortunately, however, his free and total testosterone levels continued to remain low (38.9 and 152 ng/dL, respectively) and he was continued on testosterone therapy. Discussion: Our patient initially presented with decreased libido, and low testosterone levels and was treated for hypogonadism, as he did not have typical Cushing’s symptoms. Due to eventual weight gain and facial edema, it was only then that work up was pursued showing hypercortisolism release, leading to a proper diagnosis of Cushing’s syndrome. Hypercortisolism can affect all parts of the body, including hormones, muscles, joints and bones. When presenting in the initial stages and with mild symptoms, the diagnosis of hypercortisolism is often challenging and can go undetected for many years. Presentation: 6/2/2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Rashelle Ripa + 2
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

6597 An Unusual Case of Klinefelter Syndrome with Both Primary and Superimposed Secondary Hypogonadism

Abstract Disclosure: A. Krueger: None. E. Pelley: None. Introduction: Klinefelter syndrome (KS) (47, XXY) is a sex-chromosome disorder that is a common cause of infertility and hypogonadism in men. Clinical phenotype includes tall stature, delayed or incomplete puberty, small testes (&amp;lt;4ml), gynecomastia, and oligo or azoospermia. The extra X chromosome leads to fibrosis and hyalinization of seminiferous tubules resulting in impaired sperm production. Leydig cells also function abnormally and fail to stimulate with LH. Common biochemical evaluation results in low serum testosterone, elevated FSH and LH concentrations, and azoospermia. Case Report: 37-year-old male presented with long standing history of low libido and a perception that he had never fully progressed through puberty. Physical exam was notable for a height of 6’ 4”, obesity, fine pubic and axillary hair, and testes &amp;lt;4mL bilaterally. Initial biochemical work up revealed low serum total testosterone 43 (ref 300-1080 ng/dL), low free testosterone 8.1 (ref 47-244 pg/mL), inappropriately normal LH 10.8 (ref 0.6-12.1 mlU/mL), and elevated FSH 28.3 (ref 1.0-12.0 mlU/mL). Patient was referred to Endocrinology. Labs were repeated with consistent results in addition to chromosome analysis which confirmed diagnosis of Klinefelter syndrome with (47, XXY) karyotype. Due to inappropriately normal LH and mixed picture of primary and superimposed secondary hypogonadism, an MRI of the pituitary was obtained and revealed an 8mm x7mm x 14mm pituitary macroadenoma. Evaluation for pituitary hypersecretion and other deficiencies was unremarkable. Conclusion: Data from the Danish National registry shows that only 25% of Klinefelter patients are correctly diagnosed. Klinefelter syndrome should be considered in the differential for the evaluation of hypogonadism and infertility. Diagnosis can be made by karyotyping. The degree of impaired spermatogenesis and testosterone production in Klinefelter syndrome can be variable. Biochemical evaluation should be interpreted in conjunction with clinical context. Patients with known causes of primary hypogonadism who demonstrate an inappropriate gonadotropin response require evaluation for causes of secondary hypogonadism. In this case, the inappropriately normal LH was the sole clue leading to the identification of his pituitary macroadenoma. Presentation: 6/1/2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Abigail Krueger + 1
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

8267 A Case of Pineal Gland Cyst and Adrenal Adenoma- Is this a New Syndrome?

Abstract Disclosure: M. Siddiqui: None. U. Rafat: None. S. Shaik: None. J.L. Gilden: None. Background: The Pineal Gland receives information through a complex multi-neuronal pathway and is responsible for the secretion of melatonin, a hormone regulated by circadian rhythm and suppressed by light stimuli. Melatonin is involved in biological rhythms and regulates immunomodulation, temperature homeostasis and maturation of hypothalamic-pituitary and gonadal axis, and can also modulate thyroid, prolactin, growth hormone, cortisol, and ACTH activity. Other effects include downregulation of thyroid activity. In addition, studies have shown that pineal body extracts can cause a minor increase in the zona glomerulosa and fasciculata of the adrenal gland. Case: A 54-year-old male with recurrent nephrolithiasis, obstructive sleep apnea and chronic rhinosinusitis, first presented to Endocrinology Clinic in 2018 for evaluation of an incidental adrenal adenoma (CT abdomen -2.8 cm, less than 10 Hounsfield units, left sided lipid rich adrenal adenoma). He had new onset erectile dysfunction, decreased libido, and fatigue. Initial lab work including LH, FSH, TSH, midnight salivary cortisol, ACTH, plasma cortisol AM, free and total testosterone, aldosterone, plasma and urine metanephrines/normetanephrines were all normal. MRI brain-1 cm thin-walled pineal cyst with internal characteristics compatible with proteinaceous benign pineal cyst. He was then lost to follow-up for 5 yrs due to the COVID pandemic. He had tried taking “testosterone protein builders”, but his symptoms remained. In addition, he now has twice weekly dull occipital headaches, relieved by ibuprofen. Lab tests-elevation in 1of 2 MN salivary cortisol samples at 0.58 mcg/dL (nl≤0.09), ACTH 12pg/mL(0-47), IGF1 261 ng/mL(50-317), and low total testosterone 222 ng/dl (250-1100) Free testosterone 36 pg/mL(35-155), borderline low TSH 0.386 µIU/ml(0.55-4.78), Free T3 and Free T4 were normal, thyroid antibodies-negative . Rest of the hormone evaluation was otherwise normal, LH 4.90 mIU/mL(1.5-9.3), FSH 11.10 mIU/mL (1.4-18.1), Prolactin 6.8 ng/mL(2.1-17.7). Thyroid Ultrasound-homogeneous echogenicity of the thyroid gland without discrete thyroid nodules. Repeat MRI brain- benign pineal cyst which was stable with no midline shift or mass effect. Repeat CT adrenal gland-lipid rich adrenal adenoma slightly reduced in size from 2.8 to 2.4 cm. Lab tests returned to normal one month later. Conclusion: Although it is unclear whether there is an exact association between this patient’s pineal cyst and adrenal adenoma, there have been intermittent hormonal abnormalities and symptoms consistent with hypogonadism and/or adrenal, also possibly related to the pineal abnormality. Although more research needs to be conducted explaining the relationship between the pineal and pituitary, and the adrenal gland, this clinical case suggests that there may be a relationship between these two abnormalities and symptoms. Presentation: 6/2/2024

Read full abstract
  • Journal IconJournal of the Endocrine Society
  • Publication Date IconOct 5, 2024
  • Author Icon Mahrukh Siddiqui + 3
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Prevalence of hypogonadism in men with and without chronic obstructive pulmonary disease: A cross-sectional study

Prevalence of hypogonadism in men with and without chronic obstructive pulmonary disease: A cross-sectional study

Read full abstract
  • Journal IconEndocrinología, Diabetes y Nutrición (English ed.)
  • Publication Date IconOct 1, 2024
  • Author Icon Horacio Matías Castro + 5
Cite IconCite
Chat PDF IconChat PDF
Save

Testosterone levels and risk of newly diagnosed type 2 diabetes mellitus in adult men: systematic review and meta-analysis.

Testosterone is a metabolically active hormone in males for metabolic homeostasis. Although the coexistence of low testosterone levels and type 2 diabetes mellitus (T2DM) have been associated, there are no reports that evaluate alterations in total testosterone (TT) levels and the risk of newly diagnosed T2DM. This review evaluates this question in adult men with high or low levels of total testosterone (TT), as well as the role played by other hormones such as free testosterone (FT), sex hormone binding globulin (SHBG), dihydrotestosterone (DHT), estrogens and testosterone bioavailable (bT). We searched for studies published up to July 30, 2023, in five databases, following a PECO strategy. We found twenty-two studies for quantitative analysis and meta-analyzed the same quantity of studies. This first meta-analysis incorporates the assessment of the risk of low TT and T2DM in longitudinal studies. 43,038 adult men are included. Our meta-analysis shows that there is an association between low TT levels and the risk of newly diagnosed T2DM (OR 1.52; 95% CI 1.10-2.10; p < 0.05; I²: 79%). It is also evident that SHBG in low TT studies behaves as a risk factor for T2DM in the same way as FT, although without statistical significance. bT behaves as a protective factor. There is no association between estrogen, DHT and T2DM. In adult men with low TT values, there is a greater risk of developing a newly diagnosed of T2DM. SHBG values in low TT patients also present a higher risk of T2DM as the same FT but without statistical significance. bT behaves as a protective factor We have not found an association between risk of T2DM and the levels of estrogen, DHT although there are very few studies that report these hormones.

Read full abstract
  • Journal IconEndocrine
  • Publication Date IconSep 9, 2024
  • Author Icon Gustavo Adolfo Vásquez-Tirado + 7
Cite IconCite
Chat PDF IconChat PDF
Save

Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysis

BackgroundPrimary hypogonadism is a recognised complication in survivors of testicular cancer. However, secondary hypogonadism can result from other causes that suppress the hypothalamic-pituitary axis, including obesity, high dose glucocorticoids, chronic end organ failure, and diabetes. The aim of this study was to explore low total serum testosterone in Australian survivors of testicular cancer and examine associations with body mass index, age, and prior chemotherapy use.MethodsClinical data including height, weight, diagnosis, treatment, and hormonal evaluations during follow-up were extracted from the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Chemocog study (2007-2012), accompanied by data from two Australian, high-volume testicular cancer centres included in the iTestis testicular cancer registry (2012-2019). Low testosterone was defined by a serum concentration of testosterone (T) < 10 nmol/L, and was classified as primary by a serum concentration of luteinising hormone (LH) > 8 IU/L, otherwise as secondary.ResultsTwo hundred eighty-five individuals with either stage 1 or advanced testicular cancer were included. Of these, 105 (37%) were treated with orchidectomy and chemotherapy. Forty-nine (17%) met criteria for low testosterone during follow-up: 21 (43%) had primary and 27 (55%) had secondary low testosterone. Survivors of testicular cancer with higher body mass index were more likely to display low testosterone, both primary (p = 0.032) and secondary (p = 0.028). Our data did not show evidence of an association between older age or chemotherapy use and low testosterone in our cohort.ConclusionsLow total serum testosterone was common in survivors of testicular cancer, and associated with a higher body mass index prior to orchidectomy, suggesting that elevated body mass index may contribute to low testosterone in this population, and that body weight, diet, and exercise should be addressed in testicular cancer follow-up.

Read full abstract
  • Journal IconBasic and Clinical Andrology
  • Publication Date IconSep 3, 2024
  • Author Icon Grace Y Kim + 11
Open Access Icon Open Access
Cite IconCite
Chat PDF IconChat PDF
Save

Frailty and the Correlation Between Total Testosterone Levels and Urinary Incontinence Among Elderly Women.

The objective was to explore the correlation between total testosterone levels and stress urinary incontinence (SUI) and urgency urinary incontinence (UUI) in older patients, emphasizing frailty. This prospective cross-sectional study included 1,328 women over 60 years of age at an incontinence specialty clinic. Participants were assessed for UI, frailty, using the Japanese Frailty Scale, and total testosterone levels. Analysis of a logistic regression model was employed for age, body mass index (BMI), and vaginal deliveries adjustment, with association and multivariate analyses to evaluate the associations with SUI and UUI. The frailty and nonfrailty groups each consisted of 664 individuals. After age, BMI, and the number of vaginal deliveries adjustment, the analysis showed a negative association between total testosterone levels and both SUI (p < 0.001) and UUI (p < 0.001) in the frailty group. Multivariate analysis revealed that, in the nonfrailty group, factors such as low total testosterone levels (p = 0.0145), diabetes (p = 0.0052), and cerebral infarction (p = 0.0254) were related to SUI, whereas no significant factors were associated with UUI. In the frailty group, factors associated with SUI included low total testosterone levels (p < 0.0001), the number of vaginal deliveries (p < 0.0001), smoking (p = 0.0240), chronic lung disease (p < 0.0248), and hypertension (p < 0.0265). Factors associated with UUI were age (p < 0.0001), low total testosterone levels (p = 0.0025), diabetes (p < 0.0001), and the number of vaginal deliveries (p = 0.0152). The study highlights the significance of incorporating the assessment of frailty and testosterone levels in addressing UI among older women, particularly in the aged population, underscoring the need for tailored approaches in this demographic.

Read full abstract
  • Journal IconInternational urogynecology journal
  • Publication Date IconAug 31, 2024
  • Author Icon Nobuo Okui + 1
Cite IconCite
Chat PDF IconChat PDF
Save

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • .
  • .
  • .
  • 10
  • 1
  • 2
  • 3
  • 4
  • 5

Popular topics

  • Latest Artificial Intelligence papers
  • Latest Nursing papers
  • Latest Psychology Research papers
  • Latest Sociology Research papers
  • Latest Business Research papers
  • Latest Marketing Research papers
  • Latest Social Research papers
  • Latest Education Research papers
  • Latest Accounting Research papers
  • Latest Mental Health papers
  • Latest Economics papers
  • Latest Education Research papers
  • Latest Climate Change Research papers
  • Latest Mathematics Research papers

Most cited papers

  • Most cited Artificial Intelligence papers
  • Most cited Nursing papers
  • Most cited Psychology Research papers
  • Most cited Sociology Research papers
  • Most cited Business Research papers
  • Most cited Marketing Research papers
  • Most cited Social Research papers
  • Most cited Education Research papers
  • Most cited Accounting Research papers
  • Most cited Mental Health papers
  • Most cited Economics papers
  • Most cited Education Research papers
  • Most cited Climate Change Research papers
  • Most cited Mathematics Research papers

Latest papers from journals

  • Scientific Reports latest papers
  • PLOS ONE latest papers
  • Journal of Clinical Oncology latest papers
  • Nature Communications latest papers
  • BMC Geriatrics latest papers
  • Science of The Total Environment latest papers
  • Medical Physics latest papers
  • Cureus latest papers
  • Cancer Research latest papers
  • Chemosphere latest papers
  • International Journal of Advanced Research in Science latest papers
  • Communication and Technology latest papers

Latest papers from institutions

  • Latest research from French National Centre for Scientific Research
  • Latest research from Chinese Academy of Sciences
  • Latest research from Harvard University
  • Latest research from University of Toronto
  • Latest research from University of Michigan
  • Latest research from University College London
  • Latest research from Stanford University
  • Latest research from The University of Tokyo
  • Latest research from Johns Hopkins University
  • Latest research from University of Washington
  • Latest research from University of Oxford
  • Latest research from University of Cambridge

Popular Collections

  • Research on Reduced Inequalities
  • Research on No Poverty
  • Research on Gender Equality
  • Research on Peace Justice & Strong Institutions
  • Research on Affordable & Clean Energy
  • Research on Quality Education
  • Research on Clean Water & Sanitation
  • Research on COVID-19
  • Research on Monkeypox
  • Research on Medical Specialties
  • Research on Climate Justice
Discovery logo
FacebookTwitterLinkedinInstagram

Download the FREE App

  • Play store Link
  • App store Link
  • Scan QR code to download FREE App

    Scan to download FREE App

  • Google PlayApp Store
FacebookTwitterTwitterInstagram
  • Universities & Institutions
  • Publishers
  • R Discovery PrimeNew
  • Ask R Discovery
  • Blog
  • Accessibility
  • Topics
  • Journals
  • Open Access Papers
  • Year-wise Publications
  • Recently published papers
  • Pre prints
  • Questions
  • FAQs
  • Contact us
Lead the way for us

Your insights are needed to transform us into a better research content provider for researchers.

Share your feedback here.

FacebookTwitterLinkedinInstagram
Cactus Communications logo

Copyright 2025 Cactus Communications. All rights reserved.

Privacy PolicyCookies PolicyTerms of UseCareers